# Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

> **NCT04771520** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 50 (estimated)

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
- Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
- Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced Melanoma
- Locally Advanced Primary Malignant Central Nervous System Neoplasm
- Locally Advanced Sarcoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Melanoma
- Metastatic Primary Malignant Central Nervous System Neoplasm
- Metastatic Sarcoma
- Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
- Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
- Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
- Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
- Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
- Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
- Prognostic Stage IIIC Breast Cancer AJCC v8
- Prognostic Stage IV Breast Cancer AJCC v8
- Stage IIIC Colorectal Cancer AJCC v8
- Stage IIIC Lung Cancer AJCC v8
- Stage IV Colorectal Cancer AJCC v8
- Stage IV Lung Cancer AJCC v8
- Stage IVA Colorectal Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Colorectal Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8
- Stage IVC Colorectal Cancer AJCC v8

## Interventions

- **DRUG:** Avapritinib

## Key facts

- **NCT ID:** NCT04771520
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-20
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-03-02

## Collaborators

- National Cancer Institute (NCI)

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04771520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04771520, "Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT04771520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*